Cardio Diagnostics Holdings Inc
CDIOW0.030USD
-0.009-23.86%
Handelsschluss 04/25, 16:00（ET）Kurse um 15 Minuten verzögert
--Marktkapitalisierung
--KGV TTM
mehr Informationen über Cardio Diagnostics Holdings Inc Unternehmen
Cardio Diagnostics Holdings, Inc. is an artificial intelligence-powered precision cardiovascular medicine company. The Company develops and commercializes a series of products for various types of cardiovascular disease and associated co-morbidities, including coronary heart disease (CHD), stroke, heart failure and diabetes, by leveraging its artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine. Its first product, Epi+Gen CHD, is an epigenetics-based clinical blood test capable of assessing near-term (three-year) risk for CHD, and its second product, PrecisionCHD, is an epigenetics-based clinical blood test for the detection of CHD. CardioInnovate360 is a research use only (RUO) solution to support the discovery, development, and validation of biopharmaceuticals for the assessment and management of cardiovascular diseases. HeartRisk is a cardiovascular risk intelligence platform that combines insights from anonymized and aggregated clinical cardiovascular data.
Unternehmensinformationen
Unternehmens-codeCDIOW
Name des UnternehmensCardio Diagnostics Holdings Inc
IPO-datumNov 23, 2021
Gegründet am2021
CEODr. Meeshanthini V. (Meesha) Dogan, Ph.D.
Anzahl der mitarbeiter- -
WertpapierartCompany Warrant
Geschäftsjahresende- -
Addresse311 W. Superior Street
StadtCHICAGO
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl60645
Telefon18552269991
Website
Unternehmens-codeCDIOW
IPO-datumNov 23, 2021
Gegründet am2021
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Elisa Luqman, Esq., J.D.
Ms. Elisa Luqman, Esq., J.D.
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Timur Dogan, Ph.D.
Mr. Timur Dogan, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Dr. Robert Philibert, M.D., Ph.D.
Dr. Robert Philibert, M.D., Ph.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
--
--
Dr. Robert Philibert, M.D., Ph.D.
Dr. Robert Philibert, M.D., Ph.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
--
--
Mr. Paul Burton, J.D.
Mr. Paul Burton, J.D.
Independent Director
Independent Director
--
--
Mr. James Intrater
Mr. James Intrater
Independent Director
Independent Director
--
--
Dr. Warren Hosseinion, M.D.
Dr. Warren Hosseinion, M.D.
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Mr. Paul Burton, J.D.
Mr. Paul Burton, J.D.
Independent Director
Independent Director
--
--
Dr. Meeshanthini V. (Meesha) Dogan, Ph.D.
Dr. Meeshanthini V. (Meesha) Dogan, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. James Intrater
Mr. James Intrater
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Elisa Luqman, Esq., J.D.
Ms. Elisa Luqman, Esq., J.D.
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Timur Dogan, Ph.D.
Mr. Timur Dogan, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Dr. Robert Philibert, M.D., Ph.D.
Dr. Robert Philibert, M.D., Ph.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
--
--
Dr. Robert Philibert, M.D., Ph.D.
Dr. Robert Philibert, M.D., Ph.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
--
--
Mr. Paul Burton, J.D.
Mr. Paul Burton, J.D.
Independent Director
Independent Director
--
--
Mr. James Intrater
Mr. James Intrater
Independent Director
Independent Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionäre
Update-Zeit: Wed, Apr 2
Update-Zeit: Wed, Apr 2
Aktionärsstatistik
Art
Aktionärsstatistik
Aktionäre
Anteil
Other
100.00%
Aktionärsstatistik
Aktionäre
Anteil
Other
100.00%
Art
Aktionäre
Anteil
Other
100.00%
Institutionelle Beteiligung
Update-Zeit: Mon, Mar 3
Update-Zeit: Mon, Mar 3
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q1
21
580.02K
0.00%
-815.90K
2024Q4
27
580.02K
0.00%
-1.17M
2024Q3
29
968.76K
0.00%
-800.56K
2024Q2
31
932.85K
0.00%
-1.50M
2024Q1
31
1.20M
0.00%
-1.20M
2023Q4
31
1.25M
0.00%
-1.14M
2023Q3
31
1.30M
0.00%
-1.11M
2023Q2
31
1.31M
0.00%
-1.11M
2023Q1
31
1.36M
0.00%
-1.02M
2022Q4
28
1.68M
0.00%
-569.48K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
DoubleLine Capital LP
--
0%
-11.64K
-100.00%
Mar 31, 2024
Virtu Americas LLC
--
0%
-14.51K
-100.00%
Jun 30, 2024
Walleye Trading, LLC
--
0%
-132.26K
-100.00%
Dec 31, 2024
RiverNorth Capital Management LLC
--
0%
-39.83K
-100.00%
Mar 31, 2024
AQR Arbitrage, LLC
--
0%
-2.79K
-100.00%
Dec 31, 2023
Susquehanna International Group, LLP
--
0%
-25.99K
-100.00%
Jun 30, 2024
Castle Creek Arbitrage, LLC
--
0%
-11.71K
-100.00%
Sep 30, 2023
Citadel Advisors LLC
--
0%
-11.63K
-100.00%
Dec 31, 2024
UBS Financial Services, Inc.
--
0%
-9.74K
-100.00%
Dec 31, 2024
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten